Here, by state-of-the-art mass spectrometry-based quantitative proteomic technology, we systematically screened the potential neo-substrates of a novel thalidomide derived cereblon modulator CC-885.
The proteomics cohort with PET-CT information (n = 8) were divided into two groups according to the SUV-max, and gene expression in these two groups of PDAC tissues was screened for glucose metabolism-correlated DEGs
